Company: RPTX
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001193125-25-103764
Chunk: 75

Company: Repare Therapeutics Inc.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 75
---
5. |

| (11) | Consists of 193,066 common shares issuable upon the exercise of options granted to Dr. Kulkarni that are currently exercisable or will become exercisable within 60 days of April 15, 2025. |

| (12) | Consists of 75,733 common shares issuable upon the exercise of options granted to Dr. Molineaux that are currently exercisable or will become exercisable within 60 days of April 15, 2025. |

| (13) | Consists of (a) 4,000 common shares held by Ms. Rhoads and (b) 161,040 common shares issuable upon the exercise of options granted to Ms. Rhoads that are currently exercisable or will become exercisable within 60 days of April 15, 2025. |

54

| (14) | Consists of (a) 8,000 common shares held by Ms. Schafer and (b) 193,066 common shares issuable upon the exercise of options granted to Ms. Schafer that are currently exercisable or will become exercisable within 60 days of April 15, 2025. |

| (15) | Consists of (a) 3,424,867 common shares beneficially owned by our directors and executive officers and (b) 2,146,239 common shares issuable upon the exercise of options granted to our current executive officers and directors that are currently exercisable or will become exercisable within 60 days of April 15, 2025. |

55

TRANSACTIONS WITH RELATED PERSONS AND INDEMNIFICATION Other than the executive officer and director compensation arrangements discussed in the sections titled “Executive Compensation” and “Non-EmployeeDirector Compensation,” and compensation to other executive officers that would have been disclosed in that section if such executive officers had been a named executive officer, we describe transactions and series of similar transactions, since January 1, 2023, in which we participated or will participate, in which:

| • |     | the amount involved exceeded or will exceed the lesser of (i) $120,000 or (ii) 1% of the average of our total assets as of December 31, 2023 and 2024; and |

| • |     | any of our directors, executive officers or holders of more than 5% of any class of our share capital at the time of such transaction, or